Suggestions
Jamie Heywood
Founder, CEO & Chairman of Alden Scientific
Jamie Heywood is the CEO and Founder of Alden Scientific, a position he has held since August 2020. He is based in Newton, Massachusetts, and has a strong background in the healthcare and biotechnology sectors.
Professional Background
Heywood has an extensive career in various leadership roles, including:
- Board Member at the International Consortium for Health Outcomes Measurement (ICHOM) since August 2019.
- Advisory Council Member for the Center for the Neuroscience of Psychedelics at Harvard Medical School and Massachusetts General Hospital since October 2020.
- Co-Founder and Board Member of AoBiome since August 2012.
- Founder and former CEO of PatientsLikeMe, where he worked from 2005 until November 2019.
He has also served in various capacities at organizations such as the ALS Therapy Development Institute and iCarbonX, showcasing his commitment to advancing healthcare outcomes and patient-centric innovations. Heywood's educational background includes a degree from the Massachusetts Institute of Technology (MIT) .1
Contributions and Recognition
Jamie Heywood is recognized for his innovative approaches in the healthcare industry, particularly in leveraging technology to improve patient outcomes. He has been involved in initiatives that emphasize the importance of data sharing and community engagement in healthcare, which has led to significant advancements in understanding and treating diseases like ALS. His work has earned him accolades, including features in Wired Magazine's "The Smart List" for his groundbreaking ideas .1
Highlights
With all of the dystopian thinking in the world today, it's important to celebrate when humans do something magical and amazing. Today is a day we can do that.
I remember a time when HIV was a death sentence like ALS, and I had the honor of learning from and working with some of the early leaders in HIV when I started the ALS Therapy Development Institute. At the time, we dreamed of a result like this, and that was our goal at ALS TDI and for my brother Stephen.
Gilead's result is frankly incredible. Over 40 years, a lethal viral condition, through continuous discovery, development, and care delivery, has gone from almost universally lethal to the point where today, there is a drug that prevents infection 100% (At least in this study).
I believe that it was the discovery and deployment of viral load as an effective proxy measure of patient outcomes that enabled this amazing and relentless advance.
I will quote Lord Kelvin: "I often say that when you can measure what you are speaking about, and express it in numbers, you know something about it;"
What a testament to what we can do with biology today when we have good targets and good measures and as Lord Kelvin asserted we "know something about it". I am so excited about what this says about the future of health, longevity, and disease management. We imagine and are working toward the day when health measurement is cost-effective, broadly available, and tuned to each individual. We know we can do this, and bio-assessment technology and AI are about to transform what we understand about health and life and how we intervene. That is why Jeff Cole and I started Alden Scientific.
Advances like this are the result of government, academics, philanthropy, and companies working together over time. Most of all this result is a testament to the dedication of patients, advocates, scientists, clinicians, and funders to build a better world.
Congratulations to Gilead Sciences and everyone who has been part of this and thank you for the inspiration and gift of life.
Slightly less stealth for those that have been curious what Jeff Cole and I have been working on for the last 2.5 years.
